Regulatory FDA delays verdict on AZ breast cancer drug PharmaphorumAfter an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.OncologyRead full story pharminent May 27, 2026 (Last updated: May 27, 2026) Pharmaphorum After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Early data for heart drug affirm Lilly’s billion-dollar bet on VerveNext: Kardigan targets IPO to support cardiology pipeline progression Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
